Fareston tablets 20 mg. №30 vial

$80.00

Manufacturer: Finland

Purpose: Blocks estrogen receptors for breast cancer treatment.

SKU: MED58355 Category:

Description

Fareston Tablets 20 mg. №30 Vial

Ingredients

Fareston tablets contain 20 mg of the active ingredient toremifene citrate. Other ingredients include lactose, magnesium stearate, microcrystalline cellulose, and colloidal silicon dioxide.

Dosage

The recommended dosage of Fareston is 60 mg (3 tablets) taken once daily. It is important to follow the dosage instructions provided by your healthcare provider.

Indications

Fareston is indicated for the treatment of advanced breast cancer in postmenopausal women with estrogen-receptor-positive tumors.

Contraindications

Do not use Fareston if you are allergic to toremifene or any other ingredients in the tablets. It is also contraindicated in pregnant and breastfeeding women.

Directions

Take Fareston orally with or without food. Swallow the tablets whole with a glass of water. Do not crush or chew the tablets.

Scientific Evidence

Studies have shown that Fareston is effective in the treatment of advanced breast cancer. Research published in the Journal of Clinical Oncology demonstrated the efficacy of toremifene in reducing tumor size and improving overall survival rates in patients.

Additional Information

It is important to regularly monitor liver function tests while taking Fareston, as the medication can affect liver enzymes. Inform your healthcare provider of any liver problems or other medical conditions before starting treatment.

Pharmacological Effects: Fareston works by blocking the effects of estrogen in breast tissue, thereby slowing or stopping the growth of cancer cells. It is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to its receptor.

Clinical Trials: Clinical trials have shown that Fareston is well-tolerated and effective in postmenopausal women with advanced breast cancer. A study published in Breast Cancer Research and Treatment reported a significant reduction in tumor size and a favorable safety profile in patients treated with toremifene.